Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer
E.A. Rayment
Tissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane, Queensland 4059, Australia
Search for more papers by this authorZ. Upton
Tissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane, Queensland 4059, Australia
Search for more papers by this authorG.K. Shooter
Tissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane, Queensland 4059, Australia
Search for more papers by this authorE.A. Rayment
Tissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane, Queensland 4059, Australia
Search for more papers by this authorZ. Upton
Tissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane, Queensland 4059, Australia
Search for more papers by this authorG.K. Shooter
Tissue Repair and Regeneration Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane, Queensland 4059, Australia
Search for more papers by this authorConflicts of interestNone declared.
Summary
Background The pathology of chronic wounds is often characterized by elevated levels of proinflammatory cytokines [e.g. tumour necrosis factor (TNF)-α and interleukin (IL)-1β], proteases [e.g. matrix metalloproteinases (MMPs)] and neutrophil elastase. MMPs specifically have been implicated by a number of studies as the major protease family responsible for the degradation of key factors critical to the ulcer’s ability to heal.
Objectives To assess individual MMPs in chronic wound fluid (CWF) in order to develop improved treatments for chronic ulcers.
Methods Collagen type I and IV zymography, immunoprecipitation followed by a substrate activity assay, and an indirect enzyme-linked immunosorbent assay were all used to analyse MMP levels in CWF.
Results Our studies demonstrate that there is excessive protease activity in CWF compared with both human serum and acute wound fluid (AWF), which can be specifically attributed to MMPs as determined through a MMP-inhibitor study. Multiple MMPs were immunoprecipitated from the CWF samples and MMP-9 was identified as the predominant protease in CWF, with significantly elevated activity levels in CWF compared with AWF. In addition, the clinical status of the ulcer is directly associated with the amounts of MMP-9 present in the wound fluid. Therefore, this study suggests that higher levels of MMP-9 in chronic wound fluid correlate with a clinically worse wound.
Conclusions In view of these results, it is hypothesized that a specific inhibitor of MMP-9 could potentially be more therapeutically effective than general MMP inhibitors in modulating chronic ulcers towards a healing state.
References
- 1 Trengove NJ, Stacey MC, Macauley S et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442–52.
- 2 Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg 1998; 126: 26S–38S.
- 3 Chen C, Schultz GS, Bloch M et al. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds. Wound Repair Regen 1999; 7: 486–94.
- 4 Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Repair Regen 1996; 4: 321–5.
- 5 Li WW, Li VW. Therapeutic angiogenesis for wound healing. Wounds 2003; 15: 3S–12S.
- 6 Ladwig GP, Robson MC, Liu R et al. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen 2002; 10: 26–37.
- 7 Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen 1999; 7: 433–41.
- 8 Kantor J, Margolis DJ. Management of leg ulcers. Semin Cutan Med Surg 2003; 22: 212–21.
- 9 Fray JM, Dickinson RP, Huggins JP et al. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem 2003; 46: 3514–25.
- 10 Wysocki AB, Kusakabe AO, Chang S et al. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. Wound Repair Regen 1999; 7: 154–65.
- 11 Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen 1999; 7: 423–32.
- 12 Okada Y, Gonoji Y, Naka K et al. Matrix metalloproteinase-9 (92-kDa gelatinase type-IV collagenase) from Ht-1080 human fibrosarcoma cells – purification and activation of the precursor and enzymatic properties. J Biol Chem 1992; 267: 21712–19.
- 13 Cook H, Stephens P, Davies KJ et al. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Investig Dermatol 2000; 115: 225–33.
- 14 Cullen B, Smith R, McCulloch E et al. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002; 10: 16–25.
- 15 Yager DR, Zhang LY, Liang H-X et al. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Investig Dermatol 1996; 107: 743–8.
- 16 Lauer G, Sollberg S, Cole M et al. Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site. FEBS Lett 2002; 531: 309–13.
- 17 Moseley R, Hilton JR, Waddington RJ et al. Comparison of oxidative stress biomarker profiles between acute and chronic wound environments. Wound Repair Regen 2004; 12: 419–29.
- 18 Gogly B, Groult N, Hornebeck W et al. Collagen zymography as a sensitive and specific technique for the determination of subpicogram levels of interstitial collagenase. Anal Biochem 1998; 255: 211–16.
- 19 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.
- 20 Lerman OZ, Galiano RD, Armour M et al. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003; 162: 303–12.
- 21 Ratliff CR, Rodeheaver GT. Use of the PUSH tool to measure venous ulcer healing. Ostomy Wound Manage 2005; 51: 58–63.
- 22 Schacke H, Docke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23–43.
- 23 Robins SP, Milne G, Duncan A et al. Increased skin collagen extractability and proportions of collagen type III are not normalized after 6 months healing of human excisional wounds. J Investig Dermatol 2003; 121: 267–72.
- 24 Muro AF, Chauhan AK, Gajovic S et al. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol 2003; 162: 149–60.
- 25 Stuart EL, Evans GS, Powers HJ. The proteolytic profile of prelabour ruptured amnion at term: a case-control study. Eur J Obstet Gynecol Reprod Biol 2007; 131: 158–62.
- 26 Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol 2000; 142: 960–4.
- 27 Grinnell F, Ho C-H, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J Investig Dermatol 1992; 98: 410–16.
- 28 Palohati M, Lauharanta L, Stephens RW et al. Proteolytic activity in leg ulcer exudate. Exp Dermatol 1993; 2: 29–37.
- 29 Weckroth M, Vaheri A, Lauharanta J et al. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Investig Dermatol 1996; 106: 1119–24.
- 30 Wysocki AB, Staianocoico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Investig Dermatol 1993; 101: 64–8.
- 31 Valleala H, Hanemaaijer R, Mandelin J et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci 2003; 73: 2413–20.
- 32 Massova I, Kotra LP, Fridman R et al. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075–95.
- 33 Somerville R, Oblander S, Apte S. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003; 4: 216.
- 34 Drinkwater SL, Smith A, Burnand KG. What can wound fluids tell us about the venous ulcer microenvironment? Int J Low Extrem Wounds 2002; 1: 184–90.
- 35 Staianocoico L, Higgins PJ, Schwartz S et al. Wound fluids: a reflection on the state of healing. Ostomy Wound Manage 2000; 46: 85S–93S.
- 36 Levy DE, Lapierre F, Liang W et al. Matrix metalloproteinase inhibitors: a structure-activity study. J Med Chem 1998; 41: 199–223.
- 37
Moses M,
Marikovsky M,
Harper J
et al.
Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing.
J Cell Biochem
1996; 60: 379–86.
10.1002/(SICI)1097-4644(19960301)60:3<379::AID-JCB9>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 38 Tarlton JF, Bailey AJ, Crawford E et al. Prognostic value of markers of collagen remodeling in venous ulcers. Wound Repair Regen 1999; 7: 347–55.
- 39 Gearing A, Thorpe S, Miller K et al. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett 2002; 81: 41–8.
- 40 Cullen B, Watt PW, Lundqvist C et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol 2002; 34: 1544–56.
